VXRT News and Press, Vaxart Inc. From 10/19/20

The9 (NCTY) -18%.Emerson Radio (MSN) -12%.American Equity Investment Life (AEL) -9% as Citi raises Brookfield Asset Management as AEL deal opens growth plan.ReWalk Robotics (RWLK) -10% on appointment of Randel Richner to the Board of Directors, effective November...

Vaxart ([[VXRT]] -5.2%) has announced topline results from preclinical studies evaluating oral COVID-19 vaccine candidate, demonstrating that all hamster models that received two oral doses of COVID-19 vaccine candidate were protected against systemic weight loss, as well as lung we...

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today the topline results from its Hamster Challenge Study. T...

Shares of Vaxart (NASDAQ: VXRT) were jumping 8.5% higher as of 10:39 a.m. EDT on Tuesday after rising as much as 19.6% earlier in the day. The big gain came following the company's announcement that it has dosed the first subject in a phase 1 study of oral table COVID-19 vaccine can...

3 Top Biotech Stocks To Buy Or Sell This Week? Biotech stocks have been exciting to follow in 2020 so far. The SPDR S&P Biotech ETF ( XBI Stock Report ) is up 27% year-to-date. One reason is that these companies are at the forefront of vaccine research. As the COVID-19...

The company has dosed the first subject in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. (VXRT) shares are up 6% in premarket in reaction to the news.The 48-subject study will examine the safety and immunogenicity of two doses of VXA-CoV2-1 in heal...

Open-label, dose ranging study to examine safety and immunogenicity First clinical data readouts in a few weeks SOUTH SAN FRANCISCO, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vacci...

When cloud data company Snowflake (NYSE: SNOW) went public last month, it captured investors' imaginations with incredible sales growth, well-known backers, and a tremendous first-day rise in stock price. But at a valuation of well over 120 times sales -- more than 80 times that...

Shares of biotech company Vaxart (NASDAQ: VXRT) rose 12.1% in September, according to data provided by S&P Global Market Intelligence . That sounds good, since the S&P 500 fell 3.9% during the month. But considering its shares were up more than 50% in the first t...

The end of the year is fast approaching. And for investors, several things are worth keeping an eye on between now and December. The presidential race is one example. The results of the November elections in the U.S. could affect the market -- positively or otherwise. Another race to pay at...